1	Pathological	Pathological	B-NP	JJ	O	3	NMOD	-1
2	animal	animal	I-NP	NN	O	3	NMOD	-1
3	models	model	I-NP	NNS	O	0	ROOT	-1
4	in	in	B-PP	IN	O	3	NMOD	-1
5	the	the	B-NP	DT	O	7	NMOD	-1
6	experimental	experimental	I-NP	JJ	O	7	NMOD	-1
7	evaluation	evaluation	I-NP	NN	O	4	PMOD	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	tumour	tumour	B-NP	NN	O	10	NMOD	-1
10	microvasculature	microvasculature	I-NP	NN	O	8	PMOD	-1
11	with	with	B-PP	IN	O	10	NMOD	-1
12	magnetic	magnetic	B-NP	JJ	O	14	NMOD	-1
13	resonance	resonance	I-NP	NN	O	14	NMOD	-1
14	imaging	imaging	I-NP	NN	O	11	PMOD	-1
15	.	.	O	.	O	3	P	-1

1	PURPOSE	PURPOSE	B-NP	NN	O	4	NMOD	-1
2	:	:	O	:	O	1	P	-1
3	The	The	B-NP	DT	O	4	NMOD	-1
4	purpose	purpose	I-NP	NN	O	8	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	this	this	B-NP	DT	O	7	NMOD	-1
7	study	study	I-NP	NN	O	5	PMOD	-1
8	was	be	B-VP	VBD	O	0	ROOT	-1
9	to	to	B-VP	TO	O	10	VMOD	-1
10	evaluate	evaluate	I-VP	VB	O	8	PRD	-1
11	the	the	B-NP	DT	O	12	NMOD	-1
12	applications	application	I-NP	NNS	O	10	OBJ	-1
13	of	of	B-PP	IN	O	12	NMOD	-1
14	magnetic	magnetic	B-NP	JJ	O	16	NMOD	-1
15	resonance	resonance	I-NP	NN	O	16	NMOD	-1
16	imaging	imaging	I-NP	NN	O	13	PMOD	-1
17	(	(	O	(	O	19	DEP	-1
18	MRI	MRI	B-NP	NN	B-protein	19	DEP	-1
19	)	)	O	)	O	16	NMOD	-1
20	,	,	O	,	O	10	P	-1
21	and	and	O	CC	O	10	VMOD	-1
22	in	in	B-PP	IN	O	10	VMOD	-1
23	particular	particular	B-NP	JJ	O	22	PMOD	-1
24	,	,	I-NP	,	O	10	P	-1
25	dynamic	dynamic	I-NP	JJ	O	27	NMOD	-1
26	contrast-enhanced	contrast-enhanced	I-NP	JJ	O	27	NMOD	-1
27	MRI	MRI	I-NP	NN	O	24	PMOD	-1
28	(	(	O	(	O	30	DEP	-1
29	DCE-MRI	DCE-MRI	B-NP	NN	B-protein	30	DEP	-1
30	)	)	O	)	O	27	NMOD	-1
31	,	,	O	,	O	27	P	-1
32	in	in	B-PP	IN	O	27	NMOD	-1
33	the	the	B-NP	DT	O	34	NMOD	-1
34	assessment	assessment	I-NP	NN	O	32	PMOD	-1
35	of	of	B-PP	IN	O	34	NMOD	-1
36	tumour	tumour	B-NP	NN	O	37	NMOD	-1
37	microvasculature	microvasculature	I-NP	NN	O	35	PMOD	-1
38	by	by	B-PP	IN	O	27	NMOD	-1
39	means	mean	B-NP	NNS	O	38	PMOD	-1
40	of	of	B-PP	IN	O	39	NMOD	-1
41	animal	animal	B-NP	NN	O	43	NMOD	-1
42	tumour	tumour	I-NP	NN	O	43	NMOD	-1
43	models	model	I-NP	NNS	O	40	PMOD	-1
44	evaluated	evaluate	B-VP	VBN	O	43	NMOD	-1
45	before	before	B-PP	IN	O	44	VMOD	-1
46	and	and	I-PP	CC	O	45	PMOD	-1
47	after	after	I-PP	IN	O	45	PMOD	-1
48	antiangiogenic	antiangiogenic	B-NP	JJ	O	49	NMOD	3	angiogenic
49	treatment	treatment	I-NP	NN	O	45	PMOD	19	treatment
50	.	.	O	.	O	8	P	-1

1	MATERIALS	MATERIALS	B-NP	NNS	O	3	NMOD	-1
2	AND	AND	I-NP	CC	O	3	NMOD	-1
3	METHODS	METHODS	I-NP	NNS	O	0	ROOT	-1
4	:	:	O	:	O	3	P	-1
5	Forty-two	Forty-two	B-NP	CD	O	7	NMOD	-1
6	MRI	MRI	I-NP	NN	O	7	NMOD	-1
7	exams	exam	I-NP	NNS	O	8	SUB	-1
8	were	be	B-VP	VBD	O	3	NMOD	-1
9	performed	perform	I-VP	VBN	O	8	VC	-1
10	with	with	B-PP	IN	O	9	VMOD	-1
11	intravascular	intravascular	B-NP	JJ	O	13	NMOD	-1
12	contrast	contrast	I-NP	NN	O	13	NMOD	-1
13	media	medium	I-NP	NNS	O	10	PMOD	-1
14	in	in	B-PP	IN	O	13	NMOD	-1
15	21	21	B-NP	CD	O	16	NMOD	-1
16	rats	rat	I-NP	NNS	O	14	PMOD	-1
17	:	:	O	:	O	8	P	-1
18	tumours	tumour	B-NP	NNS	O	8	VMOD	-1
19	were	be	B-VP	VBD	O	8	VMOD	-1
20	induced	induce	I-VP	VBN	O	19	VC	17	induced
21	by	by	B-PP	IN	O	20	VMOD	-1
22	subcutaneous	subcutaneous	B-NP	JJ	O	23	NMOD	-1
23	injection	injection	I-NP	NN	O	21	PMOD	0
24	of	of	B-PP	IN	O	23	NMOD	-1
25	colon	colon	B-NP	NN	B-cell_type	27	NMOD	-1
26	carcinoma	carcinoma	I-NP	NN	I-cell_type	27	NMOD	-1
27	cells	cell	I-NP	NNS	I-cell_type	24	PMOD	-1
28	in	in	B-PP	IN	O	20	VMOD	-1
29	7	7	B-NP	CD	O	30	NMOD	-1
30	rats	rat	I-NP	NNS	O	34	NMOD	-1
31	and	and	O	CC	O	34	NMOD	-1
32	mammary	mammary	B-NP	JJ	B-cell_type	34	NMOD	-1
33	adenocarcinoma	adenocarcinoma	I-NP	NN	I-cell_type	34	NMOD	-1
34	cells	cell	I-NP	NNS	I-cell_type	28	PMOD	-1
35	in	in	B-PP	IN	O	20	VMOD	-1
36	14	14	B-NP	CD	O	37	NMOD	-1
37	rats	rat	I-NP	NNS	O	35	PMOD	-1
38	.	.	O	.	O	3	P	-1

1	Perfusion	Perfusion	B-NP	NN	O	4	NMOD	0
2	and	and	I-NP	CC	O	4	NMOD	-1
3	permeability	permeability	I-NP	NN	O	4	NMOD	-1
4	parameters	parameter	I-NP	NNS	O	9	SUB	-1
5	of	of	B-PP	IN	O	4	NMOD	-1
6	the	the	B-NP	DT	O	8	NMOD	-1
7	implanted	implant	I-NP	VBN	O	8	NMOD	19	implanted
8	tumours	tumour	I-NP	NNS	O	5	PMOD	-1
9	were	be	B-VP	VBD	O	0	ROOT	-1
10	evaluated	evaluate	I-VP	VBN	O	9	VC	-1
11	by	by	B-PP	IN	O	10	VMOD	-1
12	using	use	B-VP	VBG	O	11	PMOD	-1
13	two	two	B-NP	CD	O	15	NMOD	-1
14	contrast	contrast	I-NP	NN	O	15	NMOD	-1
15	media	medium	I-NP	NNS	O	12	OBJ	-1
16	(	(	O	(	O	20	DEP	-1
17	B22956/1	B22956/1	B-NP	NN	B-protein	19	NMOD	-1
18	and	and	O	CC	O	19	NMOD	-1
19	Gd-DTPA37-albumin	Gd-DTPA37-albumin	B-NP	NN	B-protein	20	DEP	-1
20	)	)	O	)	O	15	NMOD	-1
21	to	to	B-VP	TO	O	22	VMOD	-1
22	establish	establish	I-VP	VB	O	12	VMOD	-1
23	response	response	B-NP	NN	O	22	OBJ	0
24	to	to	B-PP	TO	O	23	NMOD	-1
25	treatment	treatment	B-NP	NN	O	24	PMOD	19	treatment
26	with	with	B-PP	IN	O	25	NMOD	-1
27	two	two	B-NP	CD	O	30	NMOD	-1
28	different	different	I-NP	JJ	O	30	NMOD	-1
29	antiangiogenic	antiangiogenic	I-NP	JJ	O	30	NMOD	3	angiogenic
30	drugs	drug	I-NP	NNS	O	26	PMOD	-1
31	(	(	O	(	O	35	DEP	-1
32	tamoxifen	tamoxifen	B-NP	NN	O	34	NMOD	-1
33	and	and	O	CC	O	34	NMOD	-1
34	SU6668	SU6668	B-NP	NN	O	35	DEP	-1
35	)	)	O	)	O	30	NMOD	-1
36	.	.	O	.	O	9	P	-1

1	These	These	B-NP	DT	O	2	NMOD	-1
2	parameters	parameter	I-NP	NNS	O	3	SUB	-1
3	were	be	B-VP	VBD	O	0	ROOT	-1
4	correlated	correlate	I-VP	VBN	O	3	VC	-1
5	with	with	B-PP	IN	O	4	VMOD	-1
6	histology	histology	B-NP	NN	O	5	PMOD	-1
7	to	to	B-VP	TO	O	8	VMOD	-1
8	obtain	obtain	I-VP	VB	O	6	NMOD	0
9	a	a	B-NP	DT	O	11	NMOD	-1
10	radiological-histological	radiological-histological	I-NP	JJ	O	11	NMOD	-1
11	map	map	I-NP	NN	O	8	OBJ	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	tumour	tumour	B-NP	NN	O	14	NMOD	-1
14	microvasculature	microvasculature	I-NP	NN	O	12	PMOD	-1
15	.	.	O	.	O	3	P	-1

1	RESULTS	RESULTS	B-NP	NNS	O	0	ROOT	0
2	:	:	O	:	O	1	P	-1
3	DCE-MRI	DCE-MRI	B-NP	NN	O	4	SUB	-1
4	revealed	reveal	B-VP	VBD	O	1	NMOD	-1
5	greater	great	B-NP	JJR	O	6	NMOD	-1
6	enhancement	enhancement	I-NP	NN	O	4	OBJ	0
7	in	in	B-PP	IN	O	6	NMOD	-1
8	the	the	B-NP	DT	O	10	NMOD	-1
9	peripheral	peripheral	I-NP	JJ	O	10	NMOD	-1
10	area	area	I-NP	NN	O	7	PMOD	-1
11	than	than	B-PP	IN	O	6	NMOD	-1
12	in	in	B-PP	IN	O	11	PMOD	-1
13	the	the	B-NP	DT	O	15	NMOD	-1
14	central	central	I-NP	JJ	O	15	NMOD	-1
15	area	area	I-NP	NN	O	12	PMOD	-1
16	in	in	B-PP	IN	O	6	NMOD	-1
17	all	all	B-NP	PDT	O	21	NMOD	-1
18	the	the	I-NP	DT	O	21	NMOD	-1
19	examined	examine	I-NP	VBN	O	21	NMOD	-1
20	animal	animal	I-NP	NN	O	21	NMOD	-1
21	models	model	I-NP	NNS	O	16	PMOD	-1
22	.	.	O	.	O	1	P	-1

1	In	In	B-PP	IN	O	33	VMOD	-1
2	the	the	B-NP	DT	O	5	NMOD	-1
3	mammary	mammary	I-NP	JJ	O	5	NMOD	-1
4	carcinoma	carcinoma	I-NP	NN	O	5	NMOD	-1
5	experiment	experiment	I-NP	NN	O	1	PMOD	-1
6	,	,	O	,	O	33	P	-1
7	vascular	vascular	B-NP	JJ	O	8	NMOD	-1
8	permeability	permeability	I-NP	NN	O	33	SUB	-1
9	measured	measure	B-VP	VBN	O	8	NMOD	-1
10	by	by	B-PP	IN	O	9	VMOD	-1
11	means	mean	B-NP	NNS	O	10	PMOD	-1
12	of	of	B-PP	IN	O	11	NMOD	-1
13	B22956/1	B22956/1	B-NP	NN	B-protein	12	PMOD	-1
14	in	in	B-PP	IN	O	9	VMOD	-1
15	the	the	B-NP	DT	O	16	NMOD	-1
16	animals	animal	I-NP	NNS	O	14	PMOD	-1
17	treated	treat	B-VP	VBN	O	16	NMOD	0
18	with	with	B-PP	IN	O	17	VMOD	-1
19	the	the	B-NP	DT	O	21	NMOD	-1
20	antiangiogenic	antiangiogenic	I-NP	JJ	O	21	NMOD	3	angiogenic
21	drug	drug	I-NP	NN	O	28	NMOD	-1
22	(	(	O	(	O	27	DEP	-1
23	0.0043317+/-0.0040418	0.0043317+/-0.0040418	B-NP	CD	O	24	NMOD	-1
24	ml/min	ml/min	I-NP	NN	O	27	DEP	-1
25	(	(	O	(	O	27	DEP	-1
26	-1	-1	B-NP	CD	O	27	DEP	-1
27	)	)	O	)	O	21	NMOD	-1
28	/ml	/ml	B-NP	NN	O	18	PMOD	-1
29	(	(	O	(	O	31	DEP	-1
30	-1	-1	B-NP	CD	O	31	DEP	-1
31	)	)	O	)	O	28	NMOD	-1
32	)	)	O	)	O	8	NMOD	-1
33	was	be	B-VP	VBD	O	52	VMOD	-1
34	significantly	significantly	B-ADJP	RB	O	35	AMOD	-1
35	less	less	I-ADJP	JJR	O	33	PRD	-1
36	than	than	B-PP	IN	O	35	AMOD	-1
37	in	in	B-PP	IN	O	36	PMOD	-1
38	untreated	untreated	B-NP	JJ	O	39	NMOD	0
39	animals	animal	I-NP	NNS	O	37	PMOD	-1
40	(	(	O	(	O	50	DEP	-1
41	0.0090460+/-0.0043680	0.0090460+/-0.0043680	B-NP	CD	O	42	NMOD	-1
42	ml/min	ml/min	I-NP	NN	O	46	NMOD	-1
43	(	(	O	(	O	45	DEP	-1
44	-1	-1	B-NP	CD	O	45	DEP	-1
45	)	)	O	)	O	46	NMOD	-1
46	/ml	/ml	B-NP	NN	O	50	DEP	-1
47	(	(	O	(	O	49	DEP	-1
48	-1	-1	B-NP	CD	O	49	DEP	-1
49	)	)	O	)	O	46	NMOD	-1
50	)	)	O	)	O	35	AMOD	-1
51	,	,	O	,	O	52	P	-1
52	whereas	whereas	O	IN	O	0	ROOT	-1
53	no	no	B-NP	DT	O	55	NMOD	-1
54	significant	significant	I-NP	JJ	O	55	NMOD	-1
55	difference	difference	I-NP	NN	O	56	SUB	-1
56	was	be	B-VP	VBD	O	52	VMOD	-1
57	observed	observe	I-VP	VBN	O	56	VC	0
58	with	with	B-PP	IN	O	57	VMOD	-1
59	Gd-DTPA-albumin	Gd-DTPA-albumin	B-NP	NN	B-protein	66	NMOD	-1
60	(	(	O	(	O	65	DEP	-1
61	13.14+/-13.94	13.14+/-13.94	B-NP	CD	O	62	NMOD	-1
62	ml/min	ml/min	I-NP	NN	O	65	DEP	-1
63	(	(	O	(	O	65	DEP	-1
64	-1	-1	B-NP	CD	O	65	DEP	-1
65	)	)	O	)	O	59	NMOD	-1
66	/ml	/ml	B-NP	NN	O	58	PMOD	-1
67	(	(	O	(	O	69	DEP	-1
68	-1	-1	B-NP	NN	O	69	DEP	-1
69	)	)	O	)	O	66	NMOD	-1
70	in	in	B-PP	IN	O	66	NMOD	-1
71	treated	treat	B-NP	VBN	O	72	NMOD	19	treated
72	animals	animal	I-NP	NNS	O	79	NMOD	-1
73	and	and	O	CC	O	75	NMOD	-1
74	18.07+/-11.92	18.07+/-11.92	B-NP	CD	O	75	NMOD	-1
75	ml/min	ml/min	I-NP	NN	O	79	NMOD	-1
76	(	(	O	(	O	78	DEP	-1
77	-1	-1	B-NP	CD	O	78	DEP	-1
78	)	)	O	)	O	75	NMOD	-1
79	/ml	/ml	B-NP	NN	O	70	PMOD	-1
80	(	(	O	(	O	82	DEP	-1
81	-1	-1	B-NP	NN	O	82	DEP	-1
82	)	)	O	)	O	79	NMOD	-1
83	in	in	B-PP	IN	O	79	NMOD	-1
84	untreated	untreated	B-NP	JJ	O	85	NMOD	0
85	animals	animal	I-NP	NNS	O	83	PMOD	-1
86	)	)	O	)	O	79	NMOD	-1
87	.	.	O	.	O	52	P	-1

1	In	In	B-PP	IN	O	11	VMOD	-1
2	the	the	B-NP	DT	O	5	NMOD	-1
3	colon	colon	I-NP	NN	O	5	NMOD	-1
4	carcinoma	carcinoma	I-NP	NN	O	5	NMOD	-1
5	experiment	experiment	I-NP	NN	O	1	PMOD	-1
6	,	,	O	,	O	11	P	-1
7	mean	mean	B-NP	JJ	O	8	NMOD	-1
8	permeability	permeability	I-NP	NN	O	10	NMOD	-1
9	and	and	I-NP	CC	O	10	NMOD	-1
10	perfusion	perfusion	I-NP	NN	O	11	SUB	0
11	decreased	decrease	B-VP	VBD	O	0	ROOT	0
12	by	by	B-PP	IN	O	11	VMOD	-1
13	51	51	B-NP	CD	O	14	NMOD	-1
14	%	%	I-NP	NN	O	25	NMOD	-1
15	(	(	O	(	O	22	DEP	-1
16	from	from	B-PP	IN	O	22	DEP	-1
17	5.2+/-1.1	5.2+/-1.1	B-NP	CD	O	16	AMOD	-1
18	to	to	I-NP	TO	O	16	AMOD	-1
19	2.5+/-0.8	2.5+/-0.8	I-NP	CD	O	16	AMOD	-1
20	ml/100	ml/100	I-NP	NN	O	21	NMOD	-1
21	ml	ml	I-NP	NN	O	16	PMOD	-1
22	)	)	O	)	O	14	NMOD	-1
23	and	and	O	CC	O	25	NMOD	-1
24	59	59	B-NP	CD	O	25	NMOD	-1
25	%	%	I-NP	NN	O	12	PMOD	-1
26	(	(	O	(	O	41	DEP	-1
27	from	from	B-PP	IN	O	41	DEP	-1
28	0.00165+/-5.1	0.00165+/-5.1	B-NP	CD	O	30	AMOD	-1
29	to	to	B-PP	TO	O	30	AMOD	-1
30	0.0067+/-4.8	0.0067+/-4.8	B-NP	CD	O	31	NMOD	-1
31	ml/min	ml/min	I-NP	NN	O	35	NMOD	-1
32	(	(	O	(	O	34	DEP	-1
33	-1	-1	B-NP	CD	O	34	DEP	-1
34	)	)	O	)	O	31	NMOD	-1
35	/ml	/ml	B-NP	NN	O	27	PMOD	-1
36	(	(	O	(	O	38	DEP	-1
37	-1	-1	B-NP	NN	O	38	DEP	-1
38	)	)	O	)	O	35	NMOD	-1
39	of	of	B-PP	IN	O	35	NMOD	-1
40	tissue	tissue	B-NP	NN	O	39	PMOD	-1
41	)	)	O	)	O	25	NMOD	-1
42	,	,	O	,	O	11	P	-1
43	respectively	respectively	B-ADVP	RB	O	11	VMOD	-1
44	,	,	O	,	O	11	P	-1
45	in	in	B-PP	IN	O	11	VMOD	-1
46	all	all	B-NP	DT	O	47	NMOD	-1
47	animals	animal	I-NP	NNS	O	45	PMOD	-1
48	after	after	B-PP	IN	O	11	VMOD	-1
49	antiangiogenic	antiangiogenic	B-NP	JJ	O	51	NMOD	3	angiogenic
50	drug	drug	I-NP	NN	O	51	NMOD	-1
51	administration	administration	I-NP	NN	O	48	PMOD	0
52	.	.	O	.	O	11	P	-1

1	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	-1
2	:	:	O	:	O	1	P	-1
3	DCE-MRI	DCE-MRI	B-NP	NN	B-protein	4	SUB	-1
4	permits	permit	B-VP	VBZ	O	1	NMOD	-1
5	a	a	B-NP	DT	O	7	NMOD	-1
6	noninvasive	noninvasive	I-NP	JJ	O	7	NMOD	-1
7	evaluation	evaluation	I-NP	NN	O	4	OBJ	-1
8	of	of	B-PP	IN	O	7	NMOD	-1
9	tumour	tumour	B-NP	NN	O	10	NMOD	-1
10	microcirculation	microcirculation	I-NP	NN	O	8	PMOD	-1
11	and	and	B-PP	CC	O	4	VMOD	-1
12	in	in	B-PP	IN	O	4	VMOD	-1
13	particular	particular	B-NP	JJ	O	12	PMOD	-1
14	of	of	B-PP	IN	O	13	NMOD	-1
15	its	its	B-NP	PRP$	O	19	NMOD	-1
16	dynamic	dynamic	I-NP	JJ	O	17	NMOD	-1
17	characteristics	characteristic	I-NP	NNS	O	19	NMOD	-1
18	and	and	I-NP	CC	O	19	NMOD	-1
19	vascularity	vascularity	I-NP	NN	O	14	PMOD	-1
20	before	before	B-PP	IN	O	12	PMOD	-1
21	and	and	I-PP	CC	O	12	PMOD	-1
22	after	after	I-PP	IN	O	12	PMOD	-1
23	antiangiogenic	antiangiogenic	B-NP	JJ	O	24	NMOD	3	angiogenic
24	treatment	treatment	I-NP	NN	O	12	PMOD	0
25	.	.	O	.	O	1	P	-1

